660 results about "Pyrrolidine" patented technology

The present invention provides a compound as shown in formula (I), and a pharmaceutically acceptable salt of the compound. The compound in the present invention exhibits a strong inhibitory effect on Lp(a) assembly, and can be used for treating cardiovascular diseases (CVD).

The invention discloses an indole-benzothiadiazole derivative as well as a preparation method and application thereof. The general structural formula of the indole-benzothiadiazole derivative provided by the invention is shown in the specification, wherein R is selected from one of methyl piperazinyl, diethylamino, azetidinyl and pyrrolidinyl. The derivative can be specifically combined and fluorescently labeled with mitochondrial RNA in cells, and has good selectivity, high fluorescence signal-to-noise ratio and excellent anti-interference capability in a complex biological system. Meanwhile, the indole-benzothiadiazole derivative provided by the invention is simple in synthetic route, easily available in raw materials, good in stability and convenient to store and use, can be specifically combined with RNA and generate strong fluorescence response, is suitable for real-time detection and imaging of in-vitro and in-vivo mitochondrial RNA, and is an efficient mitochondrial RNA micromolecular fluorescent probe.

Described herein are lithium-metal rechargeable electrochemical cells comprising a lithium-metal negative electrode, a positive electrode, and a liquid electrolyte. The liquid electrolyte comprises a core mixture and a diluent. The diluent comprises a fluorinated ether. The core mixture comprises a set of salts and a set of solvents. The set of solvents comprises a pyrrolidinium-containing ionic liquid and a molecular solvent. The molecular solvent is a non-fluorinated ether, for example including but not limited to 1,2-dimethoxyethane. In some examples, the electrolyte further comprises an electrolyte additive, for example including but not limited to tris(trimethylsilyl)phosphate. In some examples, the set of salts comprises one or more imide-containing lithium salts. In some examples, the set of salts comprises lithium bis(fluorosulfonyl)imide and an additional salt and the mole fraction of lithium bis(fluorosulfonyl)imide in the set of salts is 0.5 or greater.

The invention discloses a fullerene pyrrolidine derivative as well as a preparation method and application thereof, and relates to the field of photoelectric functional materials. The structural general formula of the fullerene pyrrolidine derivative is # imgabs0, and fullerene, amino acids with different carbon chain lengths and aromatic aldehyde are subjected to Prato reaction to generate the fullerene pyrrolidine derivative. The fullerene pyrrolidine derivative provided by the invention is used as an electron transport layer material, can significantly improve the performance of a photoelectric device, has excellent chemical stability and environmental adaptability, and greatly enhances the stability of the device. In addition, the preparation method of the fullerene pyrrolidine derivative is simple, convenient and efficient, the operation condition is mild, and the manufacturing cost of a device is reduced.

An electrolyte membrane for a battery that cycles lithium ions includes a sulfide-based solid electrolyte, a polymer binder, an inorganic filler, an inorganic lithium salt, and an ionic liquid. The sulfide-based solid electrolyte includes lithium sulfide (Li2S) and at least one element selected from the group consisting of phosphorus (P), tin (Sn), silicon (Si), germanium (Ge), boron (B), gallium (Ga), and aluminum (Al). The ionic liquid includes substantially equimolar amounts of a cation and an anion. The cation includes a complex of lithium (Li+) and an ethylene glycol dimethyl ether, an imidazolium ion, a piperidinium ion, a pyrrolidinium ion, an ammonium ion, a phosphonium ion, or a combination thereof. The anion includes an arsenate ion, a phosphate ion, a sulfonylimide ion, a borate ion, a chlorate ion, or a combination thereof.

The invention provides an anti-hair-loss and hair-growing product containing plant extract components and a preparation method thereof, and relates to the field of wash supplies, the anti-hair-loss and hair-growing product is prepared from the following raw materials by weight: 50-80 parts of water, 5-10 parts of propylene glycol, 1-5 parts of 1, 3-propylene glycol, 1-5 parts of 1, 3-propylene glycol, and 1-5 parts of 1, 3-propylene glycol. The composition is prepared from the following components in parts by weight: 0.1 to 1 part of 1, 2-pentanediol, 0.1 to 1 part of pyrrolidinyl diaminopyrimidine oxide, 0.1 to 0.5 part of diaminopyrimidine oxide, 0.01 to 0.02 part of caffeine, 0.01 to 0.1 part of adenosine, 0.05 to 0.2 part of vitamin B6, 0.01 to 0.5 part of biotin tripeptide-1, 0.1 to 1 part of dipotassium glycyrrhizinate, 0.02 to 0.05 part of ethylenediamine tetraacetic acid, 0.1 to 1 part of D panthenol, 0.2 to 1 part of p-hydroxyacetophenone, 0.01 to 1 part of 1, 2-pentanediol, 0.1 to 1 part of 1, 2-pentanediol, 0.1 to 1 part of 2, 2-pentanediol, 0.1 to 1 part of 2, 2-pentanediol, 0.1 to 1 part of 2, 2- The composition comprises the following components in parts by weight: 1-2 parts of 1, 2-hexanediol, 0.1-0.5 part of citric acid, 1-2 parts of 1, 3-butanediol, 0.01-1 part of NMN and 3-5 parts of a plant extract. According to the present invention, the extraction method of the plant extract in the raw materials is specifically adjusted so as to significantly reduce the content of the pigment and the odor substance in the extract, such that the obtained hair growing liquid has characteristics of good hair growing effect, light color and light drug taste, can be easily accepted by consumers, and is suitable for large-scale promotion and application.

The invention belongs to the technical field of polyoxyethylene ether production, and particularly relates to a pyrrolidine compound polyoxyethylene ether composition and a preparation method thereof.The reaction speed is further increased and N-hydroxyethyl pyrrolidine is prevented from being oxidized and discolored by adopting a negative-pressure feeding mode in a reactor, so that the yield of N-hydroxyethyl pyrrolidine is increased, and the production cost is reduced. The pyrrolidine polyoxyethylene ether composition is prepared by mixing pyrrolidine polyoxyethylene ether with different polymerization numbers, pyrrolidine polyoxyethylene ether sodium sulfate and pyrrolidine polyoxyethylene ether sodium carboxylate according to a certain mass ratio, and the proportion of pyrrolidine polyoxyethylene ether with different lengths can be adjusted in the composition. The balance of hydrophilicity and hydrophobicity is changed, so that excellent hydrophobic-hydrophilic, dispersion and wettability properties are realized.

The invention belongs to the technical field of polyether polyol preparation, and discloses a synthesis method of propylene glycol polyether. The synthesis method comprises the following steps: mixing propylene glycol, an organic boron catalyst and a cocatalyst, then introducing alkylene oxide at 10-80 DEG C for reaction, adding a solvent into a reaction system after the reaction is finished, and carrying out reduced pressure distillation, washing and drying to obtain propylene glycol polyether, the cocatalyst is selected from one or a combination of at least two of trimethylphosphine, triethylphosphine, triphenylphosphine, tris (dimethylamino) phosphine and tripyrrolidine phosphine. According to the invention, the organic boron catalyst and the cocatalyst phosphine salt are matched for use, and the cocatalyst is selected, so that the reaction can be carried out under a relatively wide temperature condition, and the propylene glycol polyether with controllable molecular weight and narrow distribution is prepared.

Pharmaceutical compositions suitable for oral administration (such as a tablet or a capsule) are provided, which comprise a therapeutically effective amount of an amorphous solid dispersion of cabozantinib, e.g., for treating a proliferative disorder. Preferably, the amorphous solid dispersion consists of (a) cabozantinib or a pharmaceutically acceptable salt thereof (such as cabozantinib(S)-malate); (b) at least one pharmaceutically acceptable carrier selected from the group consisting of hydroxypropyl methyl cellulose acetate succinate (HPMC-AS), polyvinyl pyrrolidine and vinyl acetate (PVP / VA) copolymer, hydroxypropyl methylcellulose phthalate (HPMCP), and mixtures thereof; (c) a pore-forming agent; and (d) a plasticizer.

The present invention is directed to pyrrolidine compounds which are agonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which orexin receptors are involved.

The present disclosure relates to solid-state forms and corresponding pharmaceutical compositions of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, and methods of treatment, including treatment of rheumatoid arthritis and juvenile idiopathic arthritis using the same. The treatment methods generally comprise administering to a patient (e.g., a pediatric patient) a therapeutically effective amount of upadacitinib as a stable liquid pharmaceutical composition or a solid dosage form, at a dose based on patient body weight.

Described herein are compounds of Formula (I): I and their pharmaceutically acceptable salts, wherein R1, R2, R3, Rp, A1, L1, L2, T1, T2, T3, T4, n1, t1, t2, and t3 are defined herein; their use as GIPR antagonists; pharmaceutical compositions containing such compounds and salts; and the use of such compounds and salts to treat or prevent, for example, obesity, weight gain, and / or T2DM.

The invention discloses an application of a novel miscellaneous [3] aromatic hydrocarbon crystal material in adsorptive separation of a pyrrolidine and tetrahydrofuran mixture and / or capture of iodine vapor, and relates to the technical field of adsorption.Firstly, the novel miscellaneous [3] aromatic hydrocarbon crystal material capable of adsorptive separation of pyrrolidine and tetrahydrofuran so as to realize iodine capture is synthesized; the application method comprises the following steps: selectively adsorbing pyrrolidine in a mixture of pyrrolidine and tetrahydrofuran by adopting the novel miscellaneous [3] aromatic hydrocarbon crystal material to obtain a pyrrolidine-miscellaneous [3] aromatic hydrocarbon crystal material, realizing separation of tetrahydrofuran and pyrrolidine, and capturing iodine vapor by adopting the pyrrolidine-miscellaneous [3] aromatic hydrocarbon crystal material. Compared with other macrocyclic aromatic hydrocarbons, the method provided by the invention not only can realize separation of tetrahydrofuran and pyrrolidine, but also has the advantages of high iodine adsorption capacity, good thermal stability and the like; meanwhile, the synthesis method has the advantages of simplicity in operation, high yield, simplicity in post-treatment, easiness in separation and purification of products and the like.

The invention discloses a carvacrol / thymol derivative with a structure as shown in the following formula (I), and pharmaceutically acceptable salts of the derivative: # imgabs0 #, wherein R is selected from 1-piperidyl or 1-pyrrolidinyl. The carvacrol / thymol derivative has remarkable inhibitory activity and high selectivity on butyrylcholine esterase, has good anti-neuroinflammation activity, can be used as a selective butyrylcholine esterase inhibitor with the anti-neuroinflammation activity, can be used for preparing medicines for preventing or treating Alzheimer's disease, and has wide application prospects. The compound has a good application prospect in treatment of Alzheimer's disease.

The present invention relates to pharmaceutical compositions containing N-(1,3-dimethylpyrazol-4-yl)sulfonyl-6-[3-(3,3, 3-trifluoro-2,2-dimethyl-propoxy)pyrazol-1-yl]-2-[(4S)-2,2,4-trimethylpyrrolidin-1-yl]pyridine-3-carboxamide, a solid dispersion of (R)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-7V-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-en indol-5-yl)cyclopropanecarboxamide, and a solid dispersion of N-[2,4-Bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxo-quinoline-3-carboxamide, including formulations of the solid dispersions into powders, granules and mini-tablets, methods for manufacturing and processing the powders, granules and mini-tablets, and methods for treating cystic fibrosis employing the pharmaceutical compositions.

The invention relates to an ionic liquid additive for nickel-copper alloy foil with high tensile strength and application of the ionic liquid additive. The ionic liquid additive comprises one or more of eutectic ionic liquid, imidazole ionic liquid, quaternary ammonium ionic liquid, pyrrolidine ionic liquid and piperidine ionic liquid. According to the invention, the problems of poor corrosion resistance and low tensile strength of pure copper foil are effectively solved, so that the performance degradation and potential safety hazard of a lithium battery are improved, the transmission efficiency problem caused by roughness is reduced, and directional reference is expected to be provided for a novel alloy foil additive.

The invention relates to the technical field of wafer packaging, and particularly discloses wafer-level packaging copper interconnection electroplating liquid and a wafer-level packaging interconnection electroplating process. According to the application, the growth of copper at an orifice is inhibited by utilizing the synergistic effect among the components such as the ammonium pyrrolidine dithiocarbamate, the chloride ions, the copper salt and the polyethylene glycol, and the thickness of a copper plating layer on the surface of the cathode is reduced by adding the anthraquinone sulfonate; and the thickness of the plating layer in the center of the through hole is increased through the synergistic effect of anthraquinone sulfonate, the leveling agent, the accelerator, the brightening agent and the inhibitor, so that the through hole can be effectively filled under the high current density, the good deep plating capacity is achieved, and the product quality can be fully improved.

The invention discloses application of a quaternary ammonium salt additive in a zinc-bromine flow battery electrolyte, and belongs to the technical field of electrochemical energy storage, the chemical name of the quaternary ammonium salt additive is N-(2-ethoxyl)-N-methyl-pyrrolidinium bromide, and the quaternary ammonium salt additive is added into the zinc-bromine flow battery electrolyte as a complexing agent of elemental bromine. According to the invention, the low-temperature range of operation of the zinc-bromine flow battery is widened, and the zinc-bromine flow battery added with the novel additive can work at-20 DEG C for more than 200 hours; the dynamic characteristics of the battery are improved, and the normal-temperature and low-temperature cycle life of the battery is prolonged.

The invention provides a fullerene pyrrolidine enantiomer mediated cholesteric liquid crystal with circular polarization luminescence property and nonlinear anti-saturated absorption property, and a preparation method and application thereof. The method comprises the following steps: dissolving C60, paraformaldehyde and (R / S)-(+ / -)-alpha-methylbenzylamine in an organic solvent, and carrying out heating reflux reaction to obtain fullerene pyrrolidine enantiomer molecules; dissolving in carbon disulfide to obtain an enantiomer solution; dissolving achiral dye molecules in a solvent to obtain a dye solution; and dropwise adding the enantiomer solution and the dye solution into thermotropic liquid crystal molecules, and drying to obtain the thermotropic liquid crystal. The method is simple, the obtained cholesteric liquid crystal system shows a characteristic fingerprint texture and has a periodic spiral structure, and the doping proportion of chiral molecules is easy to adjust; the composite system has good time stability and is not prone to phase separation; the liquid crystal platform shows good circular polarization luminescence performance and third-order nonlinear optical property, and is a cholesteric liquid crystal platform with an integrated function.

The invention relates to the technical field of ionic liquid synthesis and catalytic synthesis of hydroxybutyl acrylate, in particular to a functional double-acid supported ionic liquid as well as a preparation method and application thereof. The functional double-acid supported ionic liquid comprises an MOFs (Metal-Organic Frameworks) material UiO-66-SO3H and a double-acid ionic liquid supported on the MOFs material. The synthesis of the double-acidified ionic liquid comprises the following steps: synthesizing a dimethyl monomer by adopting imidazole, pyrrolidine or morpholine; reacting the dimethyl monomer with 1, 4-butane sultone to generate sulfonic acid inner salt; and acidifying sulfonic acid internal hydrochloric acid. The functionalized double-acid supported ionic liquid has the advantages that the heat stability and the reusability are good; the product is immiscible with an organic reaction solvent and is easier to separate and recover; as a catalyst for catalyzing esterification reaction, the catalytic activity is obviously improved; as a solid catalyst in an esterification reaction, the catalyst can be applied to a fixed bed reactor, continuous esterification is realized, and the productivity is improved.

The disclosure provides compositions configured for oral use, pouched products including such compositions, and methods of manufacturing the compositions and products. Example compositions configured for oral use include a filler component, water, and a 3-(1-methylpyrrolidin-2-yl)pyridine bearing one or more substituents on the pyridine ring.

The invention provides a pyrrolidinyl diaminopyrimidine oxide supramolecular nano-vesicle as well as a preparation method and application thereof, and relates to the technical field of cosmetics. Comprising the following components: pyrrolidinyl diaminopyrimidine oxide, glycyrrhizic acid, acetyl tetrapeptide-2, a cosolvent and a solvent, the prepared pyrrolidinyl diaminopyrimidine oxide supramolecular nanovesicles can significantly improve the solubility and hair follicle targeting property of pyrrolidinyl diaminopyrimidine oxide, have the advantages of high encapsulation efficiency, large drug loading capacity, good stability and high safety, can effectively promote the anti-hair loss active factor pyrrolidinyl diaminopyrimidine oxide to accurately act on hair follicle cells, and can effectively inhibit hair loss. And the efficient anti-falling effect is achieved. The pyrrolidinyl diaminopyrimidine oxide supramolecular nano-vesicle provided by the invention is simple in preparation process, accurate in dosage and suitable for large-scale production.

The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment (including treatment of rheumatoid arthritis), kits, methods of synthesis, and products-by-process.

A medicament for treatment or prevention of interstitial lung disease, and of a disease or symptom accompanied by systemic sclerosis in a subject, the medicament comprising, as an effective ingredient, 1-{2-[(3S,4R)-1-{[(3R,4R)-1-cyclopentyl-3-fluoro-4-(4-methoxyphenyl)pyrrolidin-3-yl]carbonyl}-4-(methoxymethyl)pyrrolidin-3-yl]-5-(trifluoromethyl)phenyl}piperidine-4-carboxylic acid, or a pharmaceutically acceptable salt or co-crystal thereof.

The invention discloses an extraction head and a method for detecting organochlorine pesticides in water by using the extraction head. According to the preparation method, 4-hydroxycarbazole is taken as a functional monomer for electro-polymerization, (benzotriazole-1-yloxy) dipyrrolidine carbon hexafluorophosphate ionic liquid (IL) is taken as a doping medium, and the composite extraction coating is obtained in an electrochemical co-deposition mode. The polymerization 4-Hydroxycarbazole-IL (HBPyU) with the ionic liquid concentration of 25 mu g / mL, the salt solution of 35% saturated sodium chloride solution, the stirring rate of 600 r / min, the extraction temperature of 50 DEG C and the extraction time of 30 min is used as an optimal extraction head, and organochlorine pesticides Hepache and Quintozene in water are analyzed and detected. Therefore, according to the technical scheme, compared with an extraction head only provided with a monomer, the coating material added with the ionic liquid has the best extraction capacity on an analyte, and the beneficial effects of high efficiency and high sensitivity are achieved.

The application discloses a kind of ultraviolet absorber with triazine ring as main structure and its preparation method and its application in aramid fiber, the ultraviolet absorber has the following structural formula: Wherein, R1, R2, R3, R4 It is the group containing phenyl or substituted phenyl, R5 It is piperidyl, piperazyl, pyrrolidinyl and one of the following structures:This ultraviolet absorber has good absorption to UVA-UVB band ultraviolet, especially in 290~320 nm range has good ultraviolet absorption, adding the ultraviolet absorber in aramid fiber can significantly improve its weather resistance and service life, keep mechanical property, delay ultraviolet degradation, reduce the direct damage of fiber.

The technology herein provides various embodiments that relate to a method of treating pulmonary hypertension in a subject in need thereof, comprising administering to the subject an effective amount of BX-912 (N-[3-[[5-bromo-4-[2-(1H-imidazol-5-yl)ethylamino]-2-pyrimidinyl]amino]phenyl]pyrrolidine-1-carboxamide).

Described is small molecule 6-methoxy-7-(3-(pyrrolidin-1-yl)propoxy)-4-(tetrahydro-2H-pyran-4-yl)quinolin-2-amine (MS152) that inhibits methyltransferases G9a / EHMT2. This inhibitor can be used for the treatment of patients with G9a / EHMT2 related diseases such as Prader-Willi Syndrome and Alzheimer's Disease. Formula (I).